21:02 , Jun 6, 2019 |  BC Innovations  |  Emerging Company Profile

Scipher: decoding drug response from protein interactions

To improve the accuracy of therapeutic response predictions, Scipher has incorporated protein-protein interaction maps into its machine learning-based analyses of patient gene expression data to spotlight pathologically relevant markers. According to Scipher Medicine Corp. CEO...
23:28 , Nov 30, 2017 |  BC Week In Review  |  Clinical News

Berg reports Phase II data for ubidecarenone in metastatic pancreatic cancer

In September, Berg LLC (Framingham, Mass.) reported data from 5 evaluable patients with advanced pancreatic cancer in a Phase II trial showing that second-line treatment with IV ubidecarenone (Coenzyme Q10; BPM 31510) alone or in...
15:17 , Sep 1, 2017 |  BC Week In Review  |  Company News

Berg, AZ to discover neurological treatments using AI

Berg LLC (Framingham, Mass.) and AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered to discover targets and therapeutics to treat neurological disorders, including Parkinson's disease. The pharma will provide Berg with its CNS fragment library, which the biotech...
22:25 , Aug 29, 2017 |  BC Extra  |  Company News

Takeda, AZ partner to develop PD candidate

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) is adding another asset to its neurology pipeline by partnering with AstraZeneca plc (LSE:AZN; NYSE:AZN) to co-develop MEDI1341, a preclinical AZ candidate to treat Parkinson's disease. AstraZeneca will receive up...
23:10 , Aug 28, 2017 |  BC Extra  |  Company News

Berg, AZ to discover neurological treatments using AI

Berg LLC (Framingham, Mass.) and AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered to discover targets and therapeutics to treat neurological disorders including Parkinson's disease (PD). The pharma will provide Berg with its CNS fragment library, which the...
22:40 , Jul 14, 2017 |  BC Extra  |  Financial News

AI newco Qrativ raises $8.3M

Artificial intelligence newco Qrativ Holdings LLC (Cambridge, Mass.) launched with $8.3 million in a series A round from Matrix Capital Management, Matrix Partners and the Mayo Clinic . Qrativ was founded this year by Murali...
21:29 , May 4, 2017 |  BC Innovations  |  Tools & Techniques

Testing intelligence

An explosion in access to high-power hardware and deep computer learning has made companies like Atomwise Inc. confident that artificial intelligence (AI) can finally deliver on its decades-old promise to accelerate drug discovery. The company...
00:28 , Mar 31, 2017 |  BC Innovations  |  Targets & Mechanisms

Cells on the rise

This year’s meeting of the American Association for Cancer Research (AACR) will keep the spotlight on immuno-oncology, where preclinical science is continuing to expand the use of different types of innate and adaptive immune cells...
20:28 , Feb 16, 2017 |  BC Week In Review  |  Clinical News

IV ubidecarenone: Ph I/II started

Berg began an open-label, U.S. Phase I/II trial to evaluate IV ubidecarenone given over 72 hours twice weekly in 28-day cycles in about 10 patients with GBM that has recurred on an Avastin bevacizumab-containing regimen....
02:16 , Jan 21, 2017 |  BioCentury  |  Tools & Techniques

Hopes in the machine

Applying machine learning tools to drug R&D could usher in a new era of effective therapies targeting causative disease drivers, higher success rates in clinical trials and real-world tools to manage adherence, prevent adverse events...